Wong Kah Keng, Hussain Faezahtul Arbaeyah, Loo Suet Kee, López José I
Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
APMIS. 2017 Dec;125(12):1092-1101. doi: 10.1111/apm.12775. Epub 2017 Oct 3.
Spermatogenesis-associated 19 (SPATA19) is a cancer/testis antigen overexpressed in various cancers. However, its protein expression profile in malignant or non-malignant tissues remains unknown. Thus, in this study, we investigated SPATA19 protein expression patterns in a panel of non-malignant human samples and primary prostate cancer (PCa) with or without benign prostatic hyperplasia (BPH) tissues. SPATA19 was absent in all non-malignant tissues investigated (n=14) except testis and prostate tissues. In terms of malignancies, all PCa cases were positive for SPATA19 exhibiting frequency between 20 and 100% (median 85%) with 63 (52.5%) and 57 (47.5%) cases demonstrating weak/moderate and strong intensities, respectively. Thirty-nine PCa cases (32.5%) contained BPH, and all BPH glands were SPATA19 positive (frequency between 20 and 100%; median 90%) with 13 (33.3%) demonstrating strong SPATA19 expression. Higher SPATA19 expression (higher frequency, intensity, or H-score) was not associated with overall survival or disease-specific survival (DFS) in all PCa cases. However, biochemical recurrence (BR) was associated with worse DFS (p = 0.005) in this cohort of 120 patients, and cases with strong SPATA19 intensity were associated with BR (p = 0.020). In conclusion, we showed that SPATA19 protein was frequently expressed in both BPH and PCa glands, and this warrants future investigations on its pathogenic roles in the disease.
精子发生相关蛋白19（SPATA19）是一种在多种癌症中过表达的癌胚抗原。然而，其在恶性或非恶性组织中的蛋白表达谱仍不清楚。因此，在本研究中，我们调查了一组非恶性人类样本以及伴有或不伴有良性前列腺增生（BPH）组织的原发性前列腺癌（PCa）中SPATA19的蛋白表达模式。在所研究的所有非恶性组织（n = 14）中，除睾丸和前列腺组织外，SPATA19均未表达。在恶性肿瘤方面，所有PCa病例的SPATA19均呈阳性，表达频率在20%至100%之间（中位数为85%），其中63例（52.5%）和57例（47.5%）分别表现为弱/中度和强强度。39例PCa病例（32.5%）伴有BPH，所有BPH腺体的SPATA19均为阳性（频率在20%至100%之间；中位数为90%），其中13例（33.3%）表现为SPATA19强表达。在所有PCa病例中，较高的SPATA19表达（更高的频率、强度或H评分）与总生存期或疾病特异性生存期（DFS）无关。然而，在这120例患者队列中，生化复发（BR）与较差的DFS相关（p = 0.005），且SPATA19强度强的病例与BR相关（p = 0.020）。总之，我们发现SPATA19蛋白在BPH和PCa腺体中均频繁表达，这值得未来对其在该疾病中的致病作用进行研究。
